Tarveda Therapeutics (formerly Blend Therapeutics) secures $38 million in Series C financing - MarketLine Financial Deals

Tarveda Therapeutics (formerly Blend Therapeutics) secures $38 million in Series C financing

Tarveda Therapeutics (formerly Blend Therapeutics) secures $38 million in Series C financing - MarketLine Financial Deals
Tarveda Therapeutics (formerly Blend Therapeutics) secures $38 million in Series C financing
Published Jan 27, 2016
3 pages — Published Jan 27, 2016
Price US$ 20.00  |  Buy this Report Now

About This Report

  
Abstract:

Tarveda Therapeutics, Inc. (formerly Blend Therapeutics, Inc.), a US-based biopharmaceutical company that discovers medicines to treat cancer, has secured $38 million in Series C financing co-led by Novo.

  
Source:
Document ID
MA164514_160208
Country
Format:
PDF Adobe Acrobat
Buy Now

MarketLine Financial Deals—MarketLine Financial Deals – Identifying and tracking major financial activity across our full scope of company and sector coverage, MarketLine Financial Deals covers mergers & acquisitions, private equity/venture capital backed buyouts, investments, and exits, IPOs and secondary and follow on offerings, and private placements and exits. Additional non-corporate financial deals including partnership agreements, joint ventures, co-development and research, licensing and co-marketing agreements are also available.

About the Author


Cite this Report

  
MLA:
MarketLine Financial Deals. "Tarveda Therapeutics (formerly Blend Therapeutics) secures $38 million in Series C financing" Jan 27, 2016. Alacra Store. Dec 10, 2016. <http://www.alacrastore.com/storecontent/MarketLine-Financial-Deals/Tarveda-Therapeutics-formerly-Blend-Therapeutics-secures-38-million-in-Series-C-financing-2052-117899>
  
APA:
MarketLine Financial Deals. (2016). Tarveda Therapeutics (formerly Blend Therapeutics) secures $38 million in Series C financing Jan 27, 2016. New York, NY: Alacra Store. Retrieved Dec 10, 2016 from <http://www.alacrastore.com/storecontent/MarketLine-Financial-Deals/Tarveda-Therapeutics-formerly-Blend-Therapeutics-secures-38-million-in-Series-C-financing-2052-117899>
  
US$ 20.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our MarketLine Financial Deals from one place.